Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02423200 · ClinicalTrials.gov registry record · Phase 2
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
A Phase 2 study, sponsored by EIP Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02423200 is a Phase 2 study that has completed, run by EIP Pharma. The registered enrollment target is 16 participants.
The verdict
NCT02423200, a Phase 2 study, has completed, sponsored by EIP Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD. The study will also evaluate the safety and tolerability of VX-745 in these patients during 6 weeks of dosing, as well as the plasma and cerebrospinal fluid concentrations of VX-745 during dosing.
Interventions
- DRUG VX-745
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02423200
The ClinicalTrials.gov registry entry for NCT02423200 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EIP Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VX-745 is the first listed.
NCT02423200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02423200 about?
NCT02423200 is a clinical study titled "Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD". This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD. The study will also evaluate the safety and tolerability of VX-745 in these patients during 6 weeks of dosing, as well as the plasma and cerebrospinal flui...
What is the current status of trial NCT02423200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-04. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02423200?
The interventions under investigation include: VX-745 (DRUG).
Who is sponsoring clinical trial NCT02423200?
This trial is sponsored by EIP Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.